Table 4.
Cox regression models for BCFi and OS by luminal PAM50 subtypes, tamoxifen treatment, and PAM50 subtype by treatment interaction in patients with ER-positive/HER2-negative tumours.
| BCFi | OS | |
|---|---|---|
| HR (95% CI); P-value | ||
| 0–10 years | ||
| (n = 217, n = 92 events) | (n = 217, n = 64 events) | |
| TAM vs control in LumAPAM50 | 0.41 (0.23–0.74); 0.003 | 0.61 (0.30–1.26); 0.18 |
| TAM vs control in LumBPAM50 | 1.19 (0.63–2.27); 0.59 | 1.76 (0.85–3.63); 0.13 |
| Interaction luminal PAM50 subtype x TAM | 0.34 (0.14–0.83); 0.02 | 0.35 (0.13–0.97); 0.04 |
| >10 yearsa | ||
| (n = 121, n = 43 events) | (n = 153, n = 74 events) | |
| TAM vs control in LumAPAM50 | 0.69 (0.35–1.37); 0.29 | 0.74 (0.44–1.25); 0.26 |
| TAM vs control in LumBPAM50 | 0.17 (0.04–0.80); 0.03 | 0.25 (0.08–0.77); 0.02 |
| Interaction luminal PAM50 subtype x TAM | 4.05 (0.74–22.1); 0.11 | 2.95 (0.85–10.2); 0.09 |
| Maximum follow-up timeb | ||
| (n = 217, n = 135 events) | (n = 217, n = 138 events) | |
| TAM vs control in LumAPAM50 | 0.52 (0.34–0.81); 0.004 | 0.71 (0.46–1.08); 0.11 |
| TAM vs control in LumBPAM50 | 0.80 (0.45–1.41); 0.44 | 0.87 (0.49–1.54); 0.63 |
| Interaction luminal PAM50 subtype x TAM | 0.65 (0.32–1.34); 0.24 | 0.82 (0.40–1.65); 0.57 |
All analyses are stratified by study region.
BCFi, breast cancer-free interval; CI, confidence interval; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; Lum, Luminal; OS, overall survival; TAM, tamoxifen.
aFrom year 10 to maximum follow-up time.
b32 and 36 years regarding BCFi and OS, respectively.